Stocks · Healthcare · Biotechnology
Sarepta Therapeutics, Inc. SRPT
$17.50 -0.40% Close, Oct 2, 2026 · NASDAQ · Market cap $1.85B
High risk
Next earnings report: Nov 4, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to -7.3% from -0.0% a year earlier.
- The stock is in a downtrend: below its 200-day average, with the 50-day average below the 200-day.
- Revenue over the last four quarters was $1.97B, down 20.4% from a year earlier, slowing from -2.2% a quarter earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 15%
- Revenue growth, 3-year CAGRTop 19%
- Revenue growth accelerationBottom 13%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 38%
- Gross marginBottom 44%
- Operating marginBottom 50%
- Accruals (lower is better)Bottom 21%
- Interest coverBottom 48%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 38%
- Free-cash-flow yieldBottom 44%
- EBITDA / enterprise valueTop 39%
- Sales / enterprise valueTop 12%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 49%
- 6-month returnBottom 21%
- 1-year return vs S&P 500Bottom 35%
- Distance from 52-week highTop 49%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 11%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyBottom 21%
- Upside to consensus price targetBottom 35%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 37%
- Maximum drawdown, 3 yearsBottom 9%
- Beta vs S&P 500 (lower is better)Bottom 35%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -2.2% | -20.4% | ↓ |
| Gross margin | 79.3% | 58.6% | ↓ |
| Operating margin | -0.0% | -7.3% | ↓ |
| FCF margin | -18.3% | -6.7% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -20.4% | -2.2% | ↓ | Bottom 15% |
| Gross margin | 58.6% | 79.3% | ↓ | Bottom 44% |
| Operating margin | -7.3% | -0.0% | ↓ | Bottom 50% |
| Net margin | -6.9% | -2.3% | ↓ | — |
| Free-cash-flow margin | -6.7% | -18.3% | ↑ | — |
| Return on invested capital | -5.3% | — | Top 38% | |
| Revenue growth, 3-year CAGR | 33.1% | — | Top 19% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -1.4%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 6.5%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -0.4 pp
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -2.5×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -1.12%
- Shareholder yield
- -1.12%
- Share count change, 1 year
- -1.1%
- Share count change, 3-year CAGR
- +5.9%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 5, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- -73.6%
- Average 2-day reaction, last 8
- -2.7%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $22.75
- Target vs current price
- +30.0%
- Analysts with a rating
- 55
- Share rating Buy or Strong Buy
- 56%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 5, 2026 | -123.0% | -2.8% | +11.2% | +30.1% | — |
| May 6, 2026 | +223.8% | +5.7% | -12.2% | -25.5% | -31.8% |
| Feb 25, 2026 | -247.6% | +0.7% | -15.8% | -6.5% | -9.1% |
| Nov 3, 2025 | -147.6% | +1.8% | -26.6% | -17.9% | -11.5% |
| Aug 6, 2025 | +142.8% | -2.9% | +12.2% | +13.1% | +40.0% |
| May 6, 2025 | -428.7% | -26.6% | -42.9% | -38.9% | -74.2% |
| Feb 26, 2025 | +8.7% | -0.1% | -3.8% | -31.2% | -62.6% |
| Nov 6, 2024 | +670.2% | +2.4% | -8.6% | +1.2% | -8.7% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.05 | $0.22 | -123.0% | $401.3M |
| May 6, 2026 | $3.16 | $0.98 | +223.8% | $730.8M |
| Feb 25, 2026 | -$3.58 | -$1.03 | -247.6% | $442.9M |
| Nov 3, 2025 | -$1.80 | -$0.73 | -147.6% | $399.4M |
| Aug 6, 2025 | $2.02 | $0.83 | +142.8% | $611.1M |
| May 6, 2025 | -$4.60 | -$0.87 | -428.7% | $744.9M |
| Feb 26, 2025 | $1.50 | $1.38 | +8.7% | $658.4M |
| Nov 6, 2024 | $0.34 | -$0.06 | +670.2% | $467.2M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (forward) | 5.4× | — | — | — |
| EV / Sales | 1.18× | — | — | Top 12% |
| Free-cash-flow yield | -7.12% | — | — | Bottom 44% |
| Earnings yield | -16.57% | — | — | Bottom 38% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- +4.3%
- 200-day average slope (20 days)
- -0.2%
- Distance from 50-day average
- -7.2%
- Distance from 200-day average
- -8.5%
- RSI (14)
- 37.9
- Relative volume
- 0.89×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 63.0%
- Volatility vs own 5-year history
- 57th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.40
- Correlation with S&P 500
- 0.25
- Current drawdown from 1-year high
- -28.4%
- Maximum drawdown, 3 years
- -92.7%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Dec 22, 2020 | Jul 25, 2025 | -93.3% | 1151 days | Not yet recovered |
| Nov 4, 2020 | Nov 9, 2020 | -17.3% | 3 days | 17 days (Dec 3, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $1.85B
- EPS, diluted (TTM)
- -$2.90
- Revenue (TTM)
- $1.97B
- 52-week range
- $14.68 – $25.32
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $701.9M | $933.0M | $1.24B | $1.90B | $2.20B |
| Gross profit | $604.8M | $793.0M | $1.09B | $1.58B | $1.32B |
| Operating income | -$459.7M | -$536.2M | -$267.8M | $218.1M | -$657.8M |
| Net income | -$418.8M | -$703.5M | -$536.0M | $235.2M | -$713.4M |
| EPS (diluted) | -$5.15 | -$8.03 | -$5.80 | $2.34 | -$7.13 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $467.2M | $658.4M | $744.9M | $611.1M | $399.4M | $442.9M | $730.8M | $401.3M |
| Net income | $33.6M | $159.0M | -$447.5M | $196.9M | -$179.9M | -$282.8M | $331.0M | -$4.9M |
| EPS (diluted) | $0.33 | $1.50 | -$4.60 | $1.89 | -$1.80 | -$3.93 | $2.88 | -$0.05 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$443.2M | -$325.3M | -$501.0M | -$205.8M | -$205.5M |
| Capital expenditure | -$38.5M | -$32.3M | -$87.3M | -$147.0M | -$102.0M |
| Free cash flow | -$481.7M | -$357.6M | -$588.3M | -$352.7M | -$307.5M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $548.5M | $0 | $0 | $0 | $11.3M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $788.5M
- Total assets
- $3.19B
- Total liabilities
- $1.66B
- Total debt
- $1.05B
- Net debt
- $474.7M
- Shareholders’ equity
- $1.53B
As of Jun 30, 2026 (filed Aug 5, 2026).
Short interest
- Shares sold short
- 25,434,681
- Days to cover
- 8.02
- Change vs previous report
- +3.3%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Jul 12, 2012
- 1-for-6